EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ambrx Biopharma's enterprise value is $565.32 Mil.
Ambrx Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $5.64 Mil. Therefore, Ambrx Biopharma's EV-to-Revenue for today is 100.29.
The historical rank and industry rank for Ambrx Biopharma's EV-to-Revenue or its related term are showing as below:
AMAM'
s EV-to-Revenue Range Over the Past 10 Years
Min: 282.79 Med: 492.61 Max: 986.75
Current: 276.16
During the past 4 years, the highest EV-to-Revenue of Ambrx Biopharma was 986.75. The lowest was 282.79. And the median was 492.61.
AMAM's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 8.18
vs AMAM: 276.16
As of today (2024-05-25), Ambrx Biopharma's stock price is $9.70.
Ambrx Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.14. Therefore, Ambrx Biopharma's PS Ratio for today is 69.78.
Ambrx Biopharma EV-to-Revenue Historical Data
The historical data trend for Ambrx Biopharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ambrx Biopharma's EV-to-Revenue
For the Biotechnology subindustry, Ambrx Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambrx Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ambrx Biopharma's EV-to-Revenue falls into.
Ambrx Biopharma's current Enterprise Value is $565.32 Mil.
Ambrx Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambrx Biopharma's share price for today is $9.70.
Ambrx Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambrx Biopharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ambrx Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ambrx Biopharma (Ambrx Biopharma) Business Description
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMAM has been successfully added to your